Clinical Trial

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2024 (before its estimated November 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
• To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06520540
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions Glucagon-Like Peptide-1 Receptor Agonists
Enrollment 72 participants
Start Date 2024-07-28
Primary Completion 2024-11-30 (estimated)
Study Completion 2024-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-25